MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
To define Phase 1/2 Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC).
Epistemonikos ID: bb5c14c48238901ad2a8ffd16f7a1c6e47d18895
First added on: May 06, 2024